Quest Diagnostics Stock News

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on PET-imaging confirmation SECAUCUS, N.J. , Oct. 27, 2025 /PRNewswire/ -- Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting diagnosis, according to a new study in Neurology® Cl...

Quest Diagnostics Incorporated announced its Q3 earnings yesterday - revenues year-to-date are $8.23bn, and net income $845m. DGX is finally demonstrating a strong post-pandemic recovery, with Q3 revenues up 13% and ambitious growth initiatives in advanced diagnostics and strategic partnerships. DGX's diverse client base, operational improvements, and recent acquisitions position it for steady,...

Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2025 Earnings Call October 21, 2025 8:30 AM EDT Company Participants Shawn Bevec - Vice President of Investor Relations James Davis - Chairman, CEO & President Sam Samad - Executive VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Elizabeth Anderson - ...

Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests.

Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024 Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66; and adjusted diluted EPS is expected to...

Quest Diagnostics (DGX) remains a buy, which is also what the consensus today said too. Quest can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas. It has proven itself as a cashflow and dividend grower, achieving strong margins among peers and similar competitor Labcorp, and making progress on FDA approvals.

Quest Diagnostics Incorporated (NYSE:DGX ) Jefferies 2025 Healthcare Services Conference September 29, 2025 4:35 PM EDT Company Participants Sam Samad - Executive VP & CFO Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay, we're going to kick it off. I'm Tycho Peterson from the life science team at Je...

SECAUCUS, N.J. , Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens.